Posted On: 11/10/2014 11:37:29 AM
Post# of 89194
ACHN Volume Alert - ACHN 12.18 Achillion Pharmaceuticals $ACHN Hit a high of 12.75 Currently 11:15 Last price 12.18 +2.07 +20.47% With a day low of 10.67 and a current volume of 12,258,331.
ACHN Achillion Pharmaceuticals Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 22 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.33 (+0.13), GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), ABBV: 63.80 (+2.30), BMY: 58.54 (+0.22)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 56 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11), RGLS: 24.03 (+1.95), ABBV: 63.80 (+2.30)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.22 (+2.11)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.22 (+2.11)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (unch), HSKA: 15.87 (-0.03), ACHN: 12.22 (+2.11), AMAG: 34.83 (-0.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.06 (+0.06), ALIM: 5.03 (-0.03), ACHN: 12.22 (+2.11), FNHC: 26.80 (+0.66), ARCP: 8.63 (-0.16), CKEC: 28.29 (+0.39), JAXB: 12.01 (+0.32), PCLN: 1,104.96 (+10.35), TESO: 16.00 (-0.06)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.08 (-0.52), PLUG: 5.40 (+0.10), NYMX: 0.72 (-0.03), INTC: 33.38 (-0.20), FOX: 33.22 (-0.02), SAPE: 24.67 (unch), GERN: 2.26 (-0.07), ACHN: 12.22 (+2.11), FOXA: 34.66 (+0.05), ODP: 6.51 (+0.01), ARCP: 8.63 (-0.16), MSFT: 48.92 (+0.24), GRPN: 7.58 (+0.08), AAPL: 109.17 (+0.16)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.22 (+2.11)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.43 (+3.59), CYTX: 0.41 (-0.02), ACHN: 12.22 (+2.11), INCY: 70.30 (+0.98), SRPT: 16.48 (+0.36)
Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 12.22 (+2.11)
Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 12.22 (+2.11)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.11 (+1.66), CLVS: 58.63 (+0.32), ARWR: 6.35 (+0.29), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), RTRX: 10.33 (-0.05), RGLS: 24.03 (+1.95), EPZM: 23.74 (-0.01), AGIO: 77.16 (+5.10), RMTI: 10.26 (-0.29), ARNA: 4.31 (+0.05), KERX: 16.49 (-0.24)
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 388.33 (+4.17), ACHN: 12.22 (+2.11), CVS: 88.72 (+0.34), N: 109.92 (+0.84), PAY: 37.15 (+0.59)
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 108.09 (+1.64), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), ABBV: 63.80 (+2.30)
Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.28 (-0.59), FBHS: 43.07 (+0.27), ACHN: 12.22 (+2.11), KBH: 16.67 (+0.33), HOV: 4.02 (+0.25)
November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 12.22 (+2.11)
ACHN Achillion Pharmaceuticals Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 22 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.33 (+0.13), GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), ABBV: 63.80 (+2.30), BMY: 58.54 (+0.22)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 56 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11), RGLS: 24.03 (+1.95), ABBV: 63.80 (+2.30)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline - ACHN: 12.22 (+2.11)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.22 (+2.11)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (unch), HSKA: 15.87 (-0.03), ACHN: 12.22 (+2.11), AMAG: 34.83 (-0.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.06 (+0.06), ALIM: 5.03 (-0.03), ACHN: 12.22 (+2.11), FNHC: 26.80 (+0.66), ARCP: 8.63 (-0.16), CKEC: 28.29 (+0.39), JAXB: 12.01 (+0.32), PCLN: 1,104.96 (+10.35), TESO: 16.00 (-0.06)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.08 (-0.52), PLUG: 5.40 (+0.10), NYMX: 0.72 (-0.03), INTC: 33.38 (-0.20), FOX: 33.22 (-0.02), SAPE: 24.67 (unch), GERN: 2.26 (-0.07), ACHN: 12.22 (+2.11), FOXA: 34.66 (+0.05), ODP: 6.51 (+0.01), ARCP: 8.63 (-0.16), MSFT: 48.92 (+0.24), GRPN: 7.58 (+0.08), AAPL: 109.17 (+0.16)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.22 (+2.11)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.43 (+3.59), CYTX: 0.41 (-0.02), ACHN: 12.22 (+2.11), INCY: 70.30 (+0.98), SRPT: 16.48 (+0.36)
Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 12.22 (+2.11)
Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 12.22 (+2.11)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.11 (+1.66), CLVS: 58.63 (+0.32), ARWR: 6.35 (+0.29), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), RTRX: 10.33 (-0.05), RGLS: 24.03 (+1.95), EPZM: 23.74 (-0.01), AGIO: 77.16 (+5.10), RMTI: 10.26 (-0.29), ARNA: 4.31 (+0.05), KERX: 16.49 (-0.24)
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 388.33 (+4.17), ACHN: 12.22 (+2.11), CVS: 88.72 (+0.34), N: 109.92 (+0.84), PAY: 37.15 (+0.59)
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 108.09 (+1.64), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), ABBV: 63.80 (+2.30)
Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.28 (-0.59), FBHS: 43.07 (+0.27), ACHN: 12.22 (+2.11), KBH: 16.67 (+0.33), HOV: 4.02 (+0.25)
November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 12.22 (+2.11)
(0)
(0)Scroll down for more posts ▼
